董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carl Gordon | 男 | Independent Director | 61 | 23.25万美元 | 未持股 | 2025-10-15 |
| Jasbir Seehra | 男 | President, Chief Executive Officer and Director | 71 | 254.02万美元 | 187.17 | 2025-10-15 |
| Nima Farzan | 男 | Independent Director | 50 | 23.90万美元 | 5.30 | 2025-10-15 |
| Julius Knowles | 男 | Independent Director | 62 | 23.90万美元 | 29.79 | 2025-10-15 |
| Jean Jacques Bienaime | -- | Chair | -- | 25.94万美元 | 2.03 | 2025-10-15 |
| Mary Ann Gray | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-15 |
| Alpna Seth | -- | Independent Director | -- | 23.85万美元 | 4.79 | 2025-10-15 |
| Mary Ann Gray | 女 | Independent Director | 73 | 24.75万美元 | 6.10 | 2025-10-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jasbir Seehra | 男 | President, Chief Executive Officer and Director | 71 | 254.02万美元 | 187.17 | 2025-10-15 |
| Keith Regnante | 男 | Chief Financial Officer and Principal Accounting Officer | 57 | 111.39万美元 | 23.60 | 2025-10-15 |
| Lorena Lerner | 女 | Chief Scientific Officer | 54 | 未披露 | 未持股 | 2025-10-15 |
| Esther Cho | 女 | Senior Vice President, General Counsel | 36 | 109.88万美元 | 14.50 | 2025-10-15 |
董事简历
中英对照 | 中文 | 英文- Carl Gordon
-
Carl Gordon，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。他曾担任OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管（1998年以来）。他目前担任Adicet Bio, Inc.（纳斯达克代码：ACET）， ArriVent Biopharma Inc.（纳斯达克代码：AVBP）， Compass Therapeutics, Inc.（纳斯达克代码：CMPX）， Keros Therapeutics, Inc.（纳斯达克代码：KROS）和Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）以及几家私人公司的董事会成员。他曾任职于Alector, Inc.（纳斯达克代码：ALEC）， Gemini Therapeutics, Inc.（前纳斯达克代码：GMTX，与Disc Medicine, Inc.合并），Kinnate Biopharma Inc.（纳斯达克代码：KNTE）， ORIC Pharmaceuticals, Inc.（纳斯达克代码：ORIC）， Passage Bio, Inc.（纳斯达克代码：PASG）， precintics Inc.（前纳斯达克代码：PRVL，被Eli Lilly收购），SpringWorks Therapeutics, Inc.（纳斯达克代码：SWTX）， Theseus Pharmaceuticals, Inc.（前纳斯达克代码：SWTX）的董事会。THRX（被Concentra Biosciences LLC收购）和Turning Point Therapeutics, Inc.（前纳斯达克股票代码：TPTX，被Bristol Myers Squibb Co.收购）。他持有Harvard College的化学学士学位，Massachusetts Institute of Technology的分子生物学博士学位，也是the Rockefeller University的研究员。
Carl Gordon,has served on Mbx Biosciences, Inc. board of directors since July 2020. He has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr. Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc. (Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr. Gordon previously served on the boards of Alector, Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University. - Carl Gordon，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。他曾担任OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管（1998年以来）。他目前担任Adicet Bio, Inc.（纳斯达克代码：ACET）， ArriVent Biopharma Inc.（纳斯达克代码：AVBP）， Compass Therapeutics, Inc.（纳斯达克代码：CMPX）， Keros Therapeutics, Inc.（纳斯达克代码：KROS）和Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）以及几家私人公司的董事会成员。他曾任职于Alector, Inc.（纳斯达克代码：ALEC）， Gemini Therapeutics, Inc.（前纳斯达克代码：GMTX，与Disc Medicine, Inc.合并），Kinnate Biopharma Inc.（纳斯达克代码：KNTE）， ORIC Pharmaceuticals, Inc.（纳斯达克代码：ORIC）， Passage Bio, Inc.（纳斯达克代码：PASG）， precintics Inc.（前纳斯达克代码：PRVL，被Eli Lilly收购），SpringWorks Therapeutics, Inc.（纳斯达克代码：SWTX）， Theseus Pharmaceuticals, Inc.（前纳斯达克代码：SWTX）的董事会。THRX（被Concentra Biosciences LLC收购）和Turning Point Therapeutics, Inc.（前纳斯达克股票代码：TPTX，被Bristol Myers Squibb Co.收购）。他持有Harvard College的化学学士学位，Massachusetts Institute of Technology的分子生物学博士学位，也是the Rockefeller University的研究员。
- Carl Gordon,has served on Mbx Biosciences, Inc. board of directors since July 2020. He has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr. Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc. (Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr. Gordon previously served on the boards of Alector, Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
- Jasbir Seehra
-
Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
Jasbir Seehra has served as a member of Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology. - Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
- Jasbir Seehra has served as a member of Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.
- Nima Farzan
-
Nima Farzan自2024年7月起担任Latigo Biotherapeutics，Inc.的首席执行官和Latigo Biotherapeutics，Inc.董事会成员。此前，法尔赞曾于2024年4月至2024年7月在专注于生命科学的风险投资公司Foresite Capital担任驻场高管。2020年3月至2024年4月，Farzan先生担任公众持股的生物技术公司Kinnate Biopharma，Inc.的首席执行官和董事会成员，在那里他将三种精准肿瘤学化合物推进了临床开发，并带领公司完成了首次公开发行股票并随后被XOMA公司收购。从2018年10月到2020年2月，Farzan先生担任多家生命科学公司的顾问，包括Emergent BioSolutions，Inc.和MODA Pharmaceuticals。2011年9月至2018年10月，Farzan先生担任过多个职务，包括担任PaxVax，Inc.的总裁、首席执行官和董事会成员，PaxVax，Inc.是一家私营特种疫苗公司（被Emergent BioSolutions收购）。在加入PaxVax之前，Farzan先生担任过多个资历不断增加的职位，包括在一家上市制药公司诺华公司担任美国市场营销副总裁，并在一家私营商业咨询公司波士顿咨询集团担任合伙人。Farzan先生自2020年3月起担任公众持股的生物制药公司Keros Therapeutics, Inc.的董事会成员。Farzan先生以优异的成绩获得了斯坦福大学的人类生物学学士学位和哈佛商学院的工商管理硕士学位。
Nima Farzan has served as Latigo Biotherapeutics, Inc.'s Chief Executive Officer and a member of Latigo Biotherapeutics, Inc.'s board of directors since July 2024. Previously, Mr. Farzan served as an Executive in Residence at Foresite Capital, a life sciences focused venture capital firm, from April 2024 to July 2024. From March 2020 to April 2024, Mr. Farzan served as Chief Executive Officer and a member of the board of directors of Kinnate Biopharma, Inc., a publicly held biotechnology company, where he advanced three precision oncology compounds into clinical development and led the company through its initial public offering and subsequent acquisition by XOMA Corporation. From October 2018 to February 2020, Mr. Farzan served as an advisor for several life sciences companies, including Emergent BioSolutions, Inc. and MODA Pharmaceuticals. From September 2011 to October 2018, Mr. Farzan served in several capacities, including as President, Chief Executive Officer and member of the board of directors of PaxVax, Inc., a privately held specialty vaccine company (acquired by Emergent BioSolutions). Prior to PaxVax, Mr. Farzan held various positions of increasing seniority, including Vice President of U.S. Marketing, at Novartis AG, a publicly held pharmaceutical company, and served as an associate at The Boston Consulting Group, a privately held business consulting firm. Mr. Farzan has served on the board of directors of Keros Therapeutics, Inc., a publicly held biopharmaceutical company, since March 2020. Mr. Farzan earned his B.A. in Human Biology with honors from Stanford University and his M.B.A. from Harvard Business School. - Nima Farzan自2024年7月起担任Latigo Biotherapeutics，Inc.的首席执行官和Latigo Biotherapeutics，Inc.董事会成员。此前，法尔赞曾于2024年4月至2024年7月在专注于生命科学的风险投资公司Foresite Capital担任驻场高管。2020年3月至2024年4月，Farzan先生担任公众持股的生物技术公司Kinnate Biopharma，Inc.的首席执行官和董事会成员，在那里他将三种精准肿瘤学化合物推进了临床开发，并带领公司完成了首次公开发行股票并随后被XOMA公司收购。从2018年10月到2020年2月，Farzan先生担任多家生命科学公司的顾问，包括Emergent BioSolutions，Inc.和MODA Pharmaceuticals。2011年9月至2018年10月，Farzan先生担任过多个职务，包括担任PaxVax，Inc.的总裁、首席执行官和董事会成员，PaxVax，Inc.是一家私营特种疫苗公司（被Emergent BioSolutions收购）。在加入PaxVax之前，Farzan先生担任过多个资历不断增加的职位，包括在一家上市制药公司诺华公司担任美国市场营销副总裁，并在一家私营商业咨询公司波士顿咨询集团担任合伙人。Farzan先生自2020年3月起担任公众持股的生物制药公司Keros Therapeutics, Inc.的董事会成员。Farzan先生以优异的成绩获得了斯坦福大学的人类生物学学士学位和哈佛商学院的工商管理硕士学位。
- Nima Farzan has served as Latigo Biotherapeutics, Inc.'s Chief Executive Officer and a member of Latigo Biotherapeutics, Inc.'s board of directors since July 2024. Previously, Mr. Farzan served as an Executive in Residence at Foresite Capital, a life sciences focused venture capital firm, from April 2024 to July 2024. From March 2020 to April 2024, Mr. Farzan served as Chief Executive Officer and a member of the board of directors of Kinnate Biopharma, Inc., a publicly held biotechnology company, where he advanced three precision oncology compounds into clinical development and led the company through its initial public offering and subsequent acquisition by XOMA Corporation. From October 2018 to February 2020, Mr. Farzan served as an advisor for several life sciences companies, including Emergent BioSolutions, Inc. and MODA Pharmaceuticals. From September 2011 to October 2018, Mr. Farzan served in several capacities, including as President, Chief Executive Officer and member of the board of directors of PaxVax, Inc., a privately held specialty vaccine company (acquired by Emergent BioSolutions). Prior to PaxVax, Mr. Farzan held various positions of increasing seniority, including Vice President of U.S. Marketing, at Novartis AG, a publicly held pharmaceutical company, and served as an associate at The Boston Consulting Group, a privately held business consulting firm. Mr. Farzan has served on the board of directors of Keros Therapeutics, Inc., a publicly held biopharmaceutical company, since March 2020. Mr. Farzan earned his B.A. in Human Biology with honors from Stanford University and his M.B.A. from Harvard Business School.
- Julius Knowles
-
Julius Knowles自2016年4月起担任董事会成员。自2014年1月起，诺尔斯先生担任Partners HealthCare的风险投资部门Partners Innovation Fund的合伙人。2012年3月至2014年1月，诺尔斯先生担任由Juno Therapeutics收购的X-BODY BioSciences Inc.的首席执行官。从2006年10月到2012年2月，诺尔斯先生在诺华负责全球技术和药物发现合作，包括担任诺华生物医学研究所战略联盟平台团队的负责人。2002年3月至2006年6月，诺尔斯先生担任Novalar Pharmaceuticals，Inc.总裁。诺尔斯先生此前曾于2001年6月至2002年3月担任Novacea，Inc.（被Transcept Pharmaceuticals，Inc.收购）业务发展副总裁，1999年10月至2001年6月担任新交所制药公司业务发展副总裁，1993年6月至1999年10月担任福泰制药，Inc.研究与发展规划总监。诺尔斯先生还在几家私营生命科学公司的董事会任职。诺尔斯先生获得卡尔顿学院化学学士学位、宾夕法尼亚大学工商管理硕士学位和加州大学伯克利分校化学硕士学位。
Julius Knowles has served as a member of board of directors since April 2016. Since January 2014 Mr. Knowles has served as a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare. From March 2012 to January 2014 Mr. Knowles served as the Chief Executive Officer of X-BODY BioSciences Inc. acquired by Juno Therapeutics, Inc.. From October 2006 to February 2012 Mr. Knowles was responsible for global technology and drug discovery collaborations at Novartis, including as the Head of the Platforms team for Strategic Alliances at Novartis Institute of Biomedical Research. From March 2002 to June 2006 Mr. Knowles served as the President of Novalar Pharmaceuticals, Inc. Mr. Knowles previously served as the Vice President of Business Development of Novacea, Inc. (acquired by Transcept Pharmaceuticals, Inc.) from June 2001 to March 2002 the Vice President of Business Development of SGX Pharmaceuticals, Inc. from October 1999 to June 2001 and the Director of Research and Development Planning at Vertex Pharmaceuticals, Inc. from June 1993 to October 1999. Mr. Knowles also serves on the board of several private life science companies. Mr. Knowles received a B.A. with distinction in Chemistry from Carleton College, an M.B.A. from the University of Pennsylvania and an M.Sc. in Chemistry from UC Berkeley. - Julius Knowles自2016年4月起担任董事会成员。自2014年1月起，诺尔斯先生担任Partners HealthCare的风险投资部门Partners Innovation Fund的合伙人。2012年3月至2014年1月，诺尔斯先生担任由Juno Therapeutics收购的X-BODY BioSciences Inc.的首席执行官。从2006年10月到2012年2月，诺尔斯先生在诺华负责全球技术和药物发现合作，包括担任诺华生物医学研究所战略联盟平台团队的负责人。2002年3月至2006年6月，诺尔斯先生担任Novalar Pharmaceuticals，Inc.总裁。诺尔斯先生此前曾于2001年6月至2002年3月担任Novacea，Inc.（被Transcept Pharmaceuticals，Inc.收购）业务发展副总裁，1999年10月至2001年6月担任新交所制药公司业务发展副总裁，1993年6月至1999年10月担任福泰制药，Inc.研究与发展规划总监。诺尔斯先生还在几家私营生命科学公司的董事会任职。诺尔斯先生获得卡尔顿学院化学学士学位、宾夕法尼亚大学工商管理硕士学位和加州大学伯克利分校化学硕士学位。
- Julius Knowles has served as a member of board of directors since April 2016. Since January 2014 Mr. Knowles has served as a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare. From March 2012 to January 2014 Mr. Knowles served as the Chief Executive Officer of X-BODY BioSciences Inc. acquired by Juno Therapeutics, Inc.. From October 2006 to February 2012 Mr. Knowles was responsible for global technology and drug discovery collaborations at Novartis, including as the Head of the Platforms team for Strategic Alliances at Novartis Institute of Biomedical Research. From March 2002 to June 2006 Mr. Knowles served as the President of Novalar Pharmaceuticals, Inc. Mr. Knowles previously served as the Vice President of Business Development of Novacea, Inc. (acquired by Transcept Pharmaceuticals, Inc.) from June 2001 to March 2002 the Vice President of Business Development of SGX Pharmaceuticals, Inc. from October 1999 to June 2001 and the Director of Research and Development Planning at Vertex Pharmaceuticals, Inc. from June 1993 to October 1999. Mr. Knowles also serves on the board of several private life science companies. Mr. Knowles received a B.A. with distinction in Chemistry from Carleton College, an M.B.A. from the University of Pennsylvania and an M.Sc. in Chemistry from UC Berkeley.
- Jean Jacques Bienaime
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mary Ann Gray
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Alpna Seth
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mary Ann Gray
-
Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来，她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年，Gray博士担任Senomyx Inc.（一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司）的董事会成员。2016年4月至2018年8月，她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月，她担任TetraLogic（一家上市的临床阶段生物制药公司，专注于肿瘤学和传染病）的董事会成员。从2005年到2016年，她还担任Acadia Pharmaceuticals的董事会成员，专注于CNS疗法的商业化。2001年至2016年，她担任罕见病公司Dyax Corp.的董事会成员，该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC（生物技术战略规划和咨询公司）的总裁。她拥有杰出的科学背景，完成了肿瘤生物学的药理学研究，包括治疗对心膜的影响，并开始了她在生物技术领域的职业生涯，作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前，她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位，并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
Mary Ann Gray has been a board member of public biotechnology companies for over 15 years and has held positions of audit committee chair, compensation committee chair and lead independent director. She has served on the boards of Keros Therapeutics, Inc. since December 2020 and Compass Therapeutics, Inc. since April 2022. She also served on the boards of RAPT Therapeutics, Inc. from December 2019 to March 2026 and Palisade Bio, Inc. (formerly Seneca Biopharmaceuticals, Inc.) from April 2021 to March 2024. During her career as a board member, she has also served on several other boards including Dyax Corp. from November 2004 until January 2016, Juniper Pharmaceuticals from April 2016 to August 2018, Sarepta Therapeutics Inc. from December 2018 to June 2022, Senomyx from 2010 to December 2018, Galena Biopharma from April 2016 to December 2017, TetraLogic from November 2014 to November 2016 and Acadia Pharmaceuticals from 2005 to June 2016. Dr. Gray has been President of Gray Strategic Advisors, LLC since April 2004, a biotechnology strategic planning and advisory firm. Following an early career as a research scientist, she spent time in scientific positions at biotech and pharmaceutical companies. This was followed by over 7 years as a sell side research analyst and over 4 years as a portfolio manager at the Federated Kaufmann Fund. Dr. Gray holds a B.S. in biology from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post doctoral work at Northwestern University Medical School and at the Yale University School of Medicine. - Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来，她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年，Gray博士担任Senomyx Inc.（一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司）的董事会成员。2016年4月至2018年8月，她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月，她担任TetraLogic（一家上市的临床阶段生物制药公司，专注于肿瘤学和传染病）的董事会成员。从2005年到2016年，她还担任Acadia Pharmaceuticals的董事会成员，专注于CNS疗法的商业化。2001年至2016年，她担任罕见病公司Dyax Corp.的董事会成员，该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC（生物技术战略规划和咨询公司）的总裁。她拥有杰出的科学背景，完成了肿瘤生物学的药理学研究，包括治疗对心膜的影响，并开始了她在生物技术领域的职业生涯，作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前，她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位，并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
- Mary Ann Gray has been a board member of public biotechnology companies for over 15 years and has held positions of audit committee chair, compensation committee chair and lead independent director. She has served on the boards of Keros Therapeutics, Inc. since December 2020 and Compass Therapeutics, Inc. since April 2022. She also served on the boards of RAPT Therapeutics, Inc. from December 2019 to March 2026 and Palisade Bio, Inc. (formerly Seneca Biopharmaceuticals, Inc.) from April 2021 to March 2024. During her career as a board member, she has also served on several other boards including Dyax Corp. from November 2004 until January 2016, Juniper Pharmaceuticals from April 2016 to August 2018, Sarepta Therapeutics Inc. from December 2018 to June 2022, Senomyx from 2010 to December 2018, Galena Biopharma from April 2016 to December 2017, TetraLogic from November 2014 to November 2016 and Acadia Pharmaceuticals from 2005 to June 2016. Dr. Gray has been President of Gray Strategic Advisors, LLC since April 2004, a biotechnology strategic planning and advisory firm. Following an early career as a research scientist, she spent time in scientific positions at biotech and pharmaceutical companies. This was followed by over 7 years as a sell side research analyst and over 4 years as a portfolio manager at the Federated Kaufmann Fund. Dr. Gray holds a B.S. in biology from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
高管简历
中英对照 | 中文 | 英文- Jasbir Seehra
Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
Jasbir Seehra has served as a member of Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.- Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
- Jasbir Seehra has served as a member of Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.
- Keith Regnante
Keith Regnante自2026年8月起担任City Therapeutics，Inc.的首席财务官。在加入City Therapeutics，Inc.之前，他于2020年2月至2026年8月在临床阶段生物制药公司Keros Therapeutics, Inc.（纳斯达克：KROS）担任首席财务官。此前，从2016年8月至2020年1月，Regnante先生在临床阶段生物技术公司Wave Life Sciences Ltd.（WVE）担任首席财务官。2014年2月至2016年8月，Regnante先生在Shire plc（前身为纳斯达克：SHPG）担任财务副总裁，该公司是一家随后被Takeda Pharmaceutical Company Limited收购的全球生物技术公司，他是该公司财务领导团队和研发领导团队的成员。在其职业生涯的早期，Regnante先生曾在阿瑞雅德公司担任研发财务主管，并在Biogen Inc.担任越来越重要的财务领导职务，包括公司财务高级总监和全球研发财务高级总监。Regnante先生的职业生涯始于波士顿咨询公司的顾问。Regnante先生获得了塔夫茨大学的经济学学士学位和麻省理工学院斯隆管理学院的工商管理硕士学位。
Keith Regnante has served as City Therapeutics, Inc.'s Chief Financial Officer since August 2026. Prior to joining City Therapeutics, Inc., he served as Chief Financial Officer of Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical stage biopharmaceutical company, from February 2020 to August 2026. Previously, from August 2016 to January 2020, Mr. Regnante served as Chief Financial Officer of Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical stage biotechnology company. From February 2014 to August 2016, Mr. Regnante served as Vice President of Finance at Shire plc (formerly Nasdaq: SHPG), a global biotechnology company subsequently acquired by Takeda Pharmaceutical Company Limited, where he was a member of the Financial Leadership Team and the R&D Leadership Team. Earlier in his career, Mr. Regnante served as Head of R&D Finance at ARIAD Pharmaceuticals, Inc. and held finance leadership positions of increasing responsibility at Biogen Inc., including Senior Director of Corporate Finance and Senior Director of Global R&D Finance. Mr. Regnante began his career as a consultant at The Boston Consulting Group. Mr. Regnante received a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.- Keith Regnante自2026年8月起担任City Therapeutics，Inc.的首席财务官。在加入City Therapeutics，Inc.之前，他于2020年2月至2026年8月在临床阶段生物制药公司Keros Therapeutics, Inc.（纳斯达克：KROS）担任首席财务官。此前，从2016年8月至2020年1月，Regnante先生在临床阶段生物技术公司Wave Life Sciences Ltd.（WVE）担任首席财务官。2014年2月至2016年8月，Regnante先生在Shire plc（前身为纳斯达克：SHPG）担任财务副总裁，该公司是一家随后被Takeda Pharmaceutical Company Limited收购的全球生物技术公司，他是该公司财务领导团队和研发领导团队的成员。在其职业生涯的早期，Regnante先生曾在阿瑞雅德公司担任研发财务主管，并在Biogen Inc.担任越来越重要的财务领导职务，包括公司财务高级总监和全球研发财务高级总监。Regnante先生的职业生涯始于波士顿咨询公司的顾问。Regnante先生获得了塔夫茨大学的经济学学士学位和麻省理工学院斯隆管理学院的工商管理硕士学位。
- Keith Regnante has served as City Therapeutics, Inc.'s Chief Financial Officer since August 2026. Prior to joining City Therapeutics, Inc., he served as Chief Financial Officer of Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical stage biopharmaceutical company, from February 2020 to August 2026. Previously, from August 2016 to January 2020, Mr. Regnante served as Chief Financial Officer of Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical stage biotechnology company. From February 2014 to August 2016, Mr. Regnante served as Vice President of Finance at Shire plc (formerly Nasdaq: SHPG), a global biotechnology company subsequently acquired by Takeda Pharmaceutical Company Limited, where he was a member of the Financial Leadership Team and the R&D Leadership Team. Earlier in his career, Mr. Regnante served as Head of R&D Finance at ARIAD Pharmaceuticals, Inc. and held finance leadership positions of increasing responsibility at Biogen Inc., including Senior Director of Corporate Finance and Senior Director of Global R&D Finance. Mr. Regnante began his career as a consultant at The Boston Consulting Group. Mr. Regnante received a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.
- Lorena Lerner
Lorena Lerner，自2024年1月起担任公司高级副总裁，研究。在此之前，勒纳博士担任公司副总裁，研究始于2022年5月。2017年9月至2022年5月，勒纳博士在Oncorus, Inc.担任多个职务，职责不断增加，包括2017年9月至2018年12月分子生物学高级总监、2019年1月至2021年11月分子生物学副总裁以及2021年12月至2022年5月研究副总裁。在加入Oncorus, Inc.之前，Lerner博士曾于2016年至2017年在Quiet Therapeutics工作，于2015年至2016年在Scholar Rock Holding Corporation工作，于2003年至2015年在AVEO制药，Inc.工作。勒纳博士在布宜诺斯艾利斯大学获得分子生物学硕士学位和生物化学博士学位。她在洛克菲勒大学完成了博士后工作。
Lorena Lerner,has served as the Company's Senior Vice President, Research since January 2024. Prior to that, Dr. Lerner served as the Company's Vice President, Research beginning in May 2022. From September 2017 to May 2022, Dr. Lerner held multiple positions of increasing responsibility at Oncorus, Inc., including Senior Director, Molecular Biology from September 2017 to December 2018, Vice President, Molecular Biology from January 2019 to November 2021 and Vice President, Research from December 2021 to May 2022. Prior to Oncorus, Inc., Dr. Lerner worked at Quiet Therapeutics from 2016 to 2017, at Scholar Rock Holding Corporation from 2015 to 2016 and at AVEO Pharmaceuticals, Inc. from 2003 to 2015. Dr. Lerner received an M.S. in Molecular Biology and a Ph.D. in Biochemistry from the University of Buenos Aires. She completed her postdoctoral work at The Rockefeller University.- Lorena Lerner，自2024年1月起担任公司高级副总裁，研究。在此之前，勒纳博士担任公司副总裁，研究始于2022年5月。2017年9月至2022年5月，勒纳博士在Oncorus, Inc.担任多个职务，职责不断增加，包括2017年9月至2018年12月分子生物学高级总监、2019年1月至2021年11月分子生物学副总裁以及2021年12月至2022年5月研究副总裁。在加入Oncorus, Inc.之前，Lerner博士曾于2016年至2017年在Quiet Therapeutics工作，于2015年至2016年在Scholar Rock Holding Corporation工作，于2003年至2015年在AVEO制药，Inc.工作。勒纳博士在布宜诺斯艾利斯大学获得分子生物学硕士学位和生物化学博士学位。她在洛克菲勒大学完成了博士后工作。
- Lorena Lerner,has served as the Company's Senior Vice President, Research since January 2024. Prior to that, Dr. Lerner served as the Company's Vice President, Research beginning in May 2022. From September 2017 to May 2022, Dr. Lerner held multiple positions of increasing responsibility at Oncorus, Inc., including Senior Director, Molecular Biology from September 2017 to December 2018, Vice President, Molecular Biology from January 2019 to November 2021 and Vice President, Research from December 2021 to May 2022. Prior to Oncorus, Inc., Dr. Lerner worked at Quiet Therapeutics from 2016 to 2017, at Scholar Rock Holding Corporation from 2015 to 2016 and at AVEO Pharmaceuticals, Inc. from 2003 to 2015. Dr. Lerner received an M.S. in Molecular Biology and a Ph.D. in Biochemistry from the University of Buenos Aires. She completed her postdoctoral work at The Rockefeller University.
- Esther Cho
Esther Cho，自2023年2月起担任Keros Therapeutics, Inc.高级副总裁、总法律顾问，并担任Keros Therapeutics, Inc.秘书。在此之前，Cho女士于2020年4月开始担任Keros Therapeutics, Inc.法律主管。在加入Keros Therapeutics, Inc.之前，Cho女士是Cooley LLP的一名合伙人，在那里她代表生命科学公司处理生命周期各个阶段的各种事务。赵女士获得了波士顿大学法学院的法学博士学位和宾夕法尼亚大学的历史学学士学位。
Esther Cho,has served as Keros Therapeutics, Inc. Senior Vice President, General Counsel since February 2023, and also serves as Keros Therapeutics, Inc. Secretary. Prior to that, Ms. Cho served as Keros Therapeutics, Inc. Head of Legal beginning in April 2020. Prior to joining Keros Therapeutics, Inc. , Ms. Cho was an associate at Cooley LLP, where she represented life science companies in a wide variety of matters through all stages of their life cycle. Ms. Cho received a J.D. from Boston University School of Law and a B.A. in History from University of Pennsylvania.- Esther Cho，自2023年2月起担任Keros Therapeutics, Inc.高级副总裁、总法律顾问，并担任Keros Therapeutics, Inc.秘书。在此之前，Cho女士于2020年4月开始担任Keros Therapeutics, Inc.法律主管。在加入Keros Therapeutics, Inc.之前，Cho女士是Cooley LLP的一名合伙人，在那里她代表生命科学公司处理生命周期各个阶段的各种事务。赵女士获得了波士顿大学法学院的法学博士学位和宾夕法尼亚大学的历史学学士学位。
- Esther Cho,has served as Keros Therapeutics, Inc. Senior Vice President, General Counsel since February 2023, and also serves as Keros Therapeutics, Inc. Secretary. Prior to that, Ms. Cho served as Keros Therapeutics, Inc. Head of Legal beginning in April 2020. Prior to joining Keros Therapeutics, Inc. , Ms. Cho was an associate at Cooley LLP, where she represented life science companies in a wide variety of matters through all stages of their life cycle. Ms. Cho received a J.D. from Boston University School of Law and a B.A. in History from University of Pennsylvania.